Episode 2 of "Not So Different: a Podcast From the Center for Biosimilars"

In this episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.
February 18, 2018
In our first episode, we brought you a discussion of biosimilar interchangeability from experts across the biosimilars landscape. Interchangeable biosimilars haven’t yet become a reality in the US marketplace, and, as of yet, there is no pharmacy-level substitution of interchangeable biosimilars for brand-name products.

However, patients and their providers may still face a change of biologic therapies when payers institute a nonmedical switch.

In today’s episode of Not So Different, you’ll hear providers and patient advocates on the issue of nonmedical switching among brand-name biologics and biosimilars in rheumatology and oncology indications.



 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.